glp-1 receptor agonists in idiopathic intracranial hypertension glp 1 Proposed pathophysiological mechanisms underlying IIH and the target Association between GLP-1 receptor agonist

Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis

Mol Biomed 5 , 42 (2024)

By neutralizing free radicals in the testes and reproductive tract, it helps ensure that the DNA remains intact and healthy

These treatments may look appealing because of faster whitening claims, but they can carry serious health risks

BPC-157 is a synthetic pentadecapeptide associated with gastric-derived cytoprotective systems and is studied for effects on fibroblast activity, endothelial signaling, angiogenesis-related pathways, and nitric oxide-linked signaling

discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data